Tralokinumab safe, effective in long-term atopic dermatitis treatment
Click Here to Manage Email Alerts
Long-term use of tralokinumab is safe and efficacious in the treatment of atopic dermatitis, according to a presentation at AAD VMX 2021.
“Moderate to severe atopic dermatitis is a chronic disease requiring chronic therapy,” study investigator Andrew Blauvelt, MD, MBA, president of Oregon Medical Research Center, told Healio. “Everyone wants to know what happens over time. Do patients lose response? Do they develop new side effects with longer use?”
The 268-week ECZTEND trial includes patients who previously were enrolled in the ECZTRA 1-8 and TraSki investigator-initiated studies.
Interim data showed those treated with tralokinumab 300 mg every other week, in addition to optional topical steroids, had improvements in itch, sleep, and AD signs and symptoms at week 56.
Investigator Global Assessment 0/1 response rate was 49.7%, while Eczema Area and Severity Index response rate was 95.1% (EASI-50) at 56 weeks. EASI-75 was reported in 82.8% of patients, EASI-90 in 61% and EASI 7, which corresponds to mild atopic dermatitis, in 79.7%.
The 2-year cohort, which included subjects who completed 52 weeks of treatment with tralokinumab and at least 56 weeks in the extension study, had EASI response rates of 93.8% (EASI-50), 82.5% (EASI-75) and 59.8% (EASI-90).
“The bottom line is that people do well over time with continued use and no new safety signals developed,” Blauvelt said. “The results are critical in reassuring both dermatologists and patients that the long-term use of their medication for their chronic disease is safe and effective for up to 2 years of use.”